Related Experiment Video
Updated: May 19, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Extended interval dosing of gentamicin in premature neonates ≤ 28-week gestation
Belal Alshaikh1, Deonne Dersch-Mills, Richard Taylor
1Division of Neonatology, Department of Pediatrics, Faculty of Medicine, University of Calgary, Alberta, Canada.
Aim:
To evaluate an extended interval dosing (EID) regimen of gentamicin in neonates ≤28-week gestation.
Methods:
In 2008, an EID regimen for gentamicin was introduced for all neonates admitted to the NICU in Calgary. The dosing interval was based on a 22 h level after the first dose of 5mg/kg. We conducted an observational study in 33 infants ≤28-week gestation on the EID regimen from the first day of life and compared gentamicin peak and trough levels with a historical control of 34 infants who received gentamicin in a dose of 2.5 mg/kg every 24 h (TID, traditional interval dosing).
Results:
In the EID group, based on the 22 h level, dosing interval was 36 h in 20 neonates and 48 h in 13 neonates. All neonates, except one, achieved therapeutic peak and trough levels. Compared to the TID group, the EID group had higher peak levels (median 9.8 μg/mL vs. 4.6 μg/mL, p < 0.001) with no difference in trough levels. With target peak levels of 5-12 μg/mL and trough levels of <2 μg/mL, a higher proportion of neonates in the TID group would need dose adjustment.
Conclusion:
In neonates ≤ 28-week gestation, an EID regimen from day one of life, using a single level 22 h after the first dose for dosing interval, achieves therapeutic peak and trough levels and more optimum peak levels as compared to a TID regimen.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Dosing: Infants and Children
Estimation of k and VD of Aminoglycosides
Dosage Regimens: Partial Pharmacokinetic Parameters

